(24)

For The Kappal Corporation

Authorised Signatory

D-5(T)/MUM/106/16/051/1992-96

Andheri Mumbai, Syndicate Chamber, 2nd Floor, Sahar Road, Andheri (East), Mumbai-400 069

CLINICAL TRIAL AGREEMENT

Made between **Dr. Anil Kakunje** having a place of business at Department of Psychiatry, Yenepoya Medical College Hospital, University Road, Deralakatte, Mangalore – 575018, India (the "Investigator"), **Yenepoya Medical College**, having a place of business at University Road, Deralakatte, Mangalore – 575018, India (the "Institution"), and **Quintiles Research (India) Private Limited,** having its branch office at 301-A-1,3rd Floor, Leela Business Park M.V Road, Andheri (East),Mumbai 400059,India ("Quintiles") representing the interests of Novartis Healthcare Private Limited (the "Sponsor").

INDIA NON JUDICIAL STAMP DUTY MAHARASHTRA

Rs. 100 0000 0000 0000 0000 3001-PB5502

FEB 02 2011 11:40

107284

PROTOCOL NUMBER:	ILO522D2301
PROTOCOL TITLE:	A multicenter, randomized, double-blind, placebocontrolled, parallel-group study to evaluate prevention of relapse in patients with schizophrenia receiving either flexible dose iloperidone (Fanapt™) or placebo in long-term use (up to 26 weeks) followed by up to 52 weeks of open label extension
PROTOCOL DATE:	4 May 2010
SPONSOR:	Novartis Healthcare Private Limited
PRINCIPAL INVESTIGATOR:	Dr. Anil Kakunje
KEY ENROLLMENT DATE: (date by which site is to enroll at least one (1) subject)	**100 Calendar Days after Site Initiation Visit**

WHEREAS, the Investigator and Institution,(hereafter, jointly, the "Site") are willing to conduct a clinical trial (the "Study"), in accordance with the above-referenced protocol and any subsequent amendments thereto (the "Protocol") and Quintiles requests the Site to undertake such Study;

NOW THEREFORE, the following is agreed:

1. Quintiles hereby appoints the Site to conduct the Study, and the Site agrees to ensure that the Site and the Site's employees, agents, and staff will conduct the Study in accordance with the Protocol, the terms of this agreement, including the Terms and Conditions attached as Attachment A, the Payment Schedule and Budget attached as Attachment B, and any other the attachments hereto, which all are incorporated by reference herein (the "Agreement"), good clinical practices ("GCPs"),, and all applicable laws and regulations. The Site hereby confirms that it has adequate time and resources to perform the Study according to the quality standards required. The Site understands and agrees that if Site has not enrolled at least one (1) subject by the Key Enrollment Date then Quintiles may terminate this Agreement in accordance with Section 5 of Attachment A.

2. Payments shall be made in accordance with the provisions set forth in Attachment B, with the last payment being made after the Site completes all its obligations hereunder, and Quintiles has received all completed case report forms ("CRFs") and, if Quintiles requests, all other Confidential Information as defined in Attachment A, Section 2 (Confidential and Proprietary Information). The Site will act as an independent contractor, and shall not be considered the employee or agent of Quintiles or Sponsor. Neither Quintiles nor Sponsor shall be responsible for any employee benefits, pensions, workers' compensation, withholding, or employment-related taxes as to the Site. The Site acknowledges and agrees that Investigator's judgment with respect to Investigator's advice to and care of each subject is not affected by the compensation Site receives hereunder. The parties agree that the payees designated below are the proper payees for this Agreement, and that payments under this Agreement will be made only to the following payees (each a "Payee", collectively the "Payees") as noted below: